A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

Researchers are looking for a better way to treat people with advanced colorectal cancer. Colorectal cancer (cancer of the colon or rectum) is one of the most common cancers worldwide. Treatments include surgery, chemotherapy, radiotherapy, and immunotherapy; however, these treatments do not work for everyone, may cause serious adverse events or may stop working eventually. New treatments and treatment combinations are needed, especially for cancers that cannot be removed with surgery or that have spread to other parts of the body (called advanced or metastatic cancer). Cells normally repair

Trial Details

NCT ID
NCT07811193
Phase
PHASE2
Sponsor
Vividion Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • VVD-133214
  • Pembrolizumab
Locations (sample)
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Morgantown, West Virginia, United States|39.62953,-79.9559
  • Buenos Aires, Buenos Aires, Argentina

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1
  • Have a known microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) tumor status confirmed per local standard of care (SoC), and …
  • No prior systemic treatment for metastatic disease and not amenable to curative resection
  • Participants must have documented MSI and/or dMMR tumor status determined as part of the routine diagnostic workup in a certified laboratory

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →